Recent developments of liposomes as nanocarriers for theranostic applications

Theranostics

Volumn 6, Issue 9, 2016, Pages 1336-1352

  Xing, Hang ^a   Hwang, Kevin ^a   Lu, Yi ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

Clinical translation; Liposomes; Multimodal imaging; Targeted therapy; Theranostics

Indexed keywords

1 MYRISTOYL 2 STEAROYL SN GLYCERO 3 PHOSPHOCHOLINE; 1,2 DIPALMITOYL SN GLYCERO 3 PHOSPHATIDYLCHOLINE; 1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOETHANOLAMINE; CISPLATIN; DOXORUBICIN; GADOTERIC ACID; GOLD NANOPARTICLE; IRINOTECAN; LIPOSOME; PACLITAXEL; PHOSPHATIDYLCHOLINE; POLYMER; SMALL INTERFERING RNA; TECEMOTIDE; UNCLASSIFIED DRUG; VANCOMYCIN; ZINC DERIVATIVE; ZINC DIPICOLYLAMINE MODIFIED POLYMERIZED POLY(DIACETYLENE); ZOLEDRONIC ACID; DRUG CARRIER;

ANTINEOPLASTIC ACTIVITY; CELL INTERACTION; CONTROLLED DRUG RELEASE; DRUG ACCUMULATION; DRUG DISTRIBUTION; DRUG FORMULATION; FLUORESCENCE IMAGING; GENE THERAPY; HUMAN; IMMUNOTHERAPY; IN VITRO STUDY; IN VIVO STUDY; LIPOSOMAL GENE DELIVERY SYSTEM; MICROARRAY ANALYSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PARTICLE SIZE; PHOTOACOUSTIC TOMOGRAPHY; POSITRON EMISSION TOMOGRAPHY; PROTEIN TARGETING; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; ANIMAL; PROCEDURES; THERANOSTIC NANOMEDICINE;

ANIMALS; DRUG CARRIERS; HUMANS; LIPOSOMES; THERANOSTIC NANOMEDICINE;

EID: 84991627514     PISSN: None     EISSN: 18387640     Source Type: Journal    
DOI: 10.7150/thno.15464     Document Type: Review

References (145)

1. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. Nat Nanotechnol. 2007; 2: 751-60
2. Ferrari M. Cancer nanotechnology: Opportunities and challenges. Nat Rev Cancer. 2005; 5: 161-71
3. Lin R, Cui HG. Supramolecular nanostructures as drug carriers. Curr Opin Chem Eng. 2015; 7: 75-83
4. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov. 2005; 4: 145-60
5. Deamer DW. From "Banghasomes" to liposomes: A memoir of Alec Bangham, 1921-2010. FASEB J. 2010; 24: 1308-10
6. Allen TM, Cullis PR. Liposomal drug delivery systems: From concept to clinical applications. Adv Drug Deliver Rev. 2013; 65: 36-48
7. Al-Jamal WT, Kostarelos K. Liposomes: From a Clinically Established Drug Delivery System to a Nanoparticle Platform for Theranostic Nanomedicine. Acc Chem Res. 2011; 44: 1094-104
8. Bangham AD, Horne RW. Negative Staining of Phospholipids and Their Structural Modification by-Surface Active Agents as Observed in Electron Microscope. J Mol Biol. 1964; 8: 660-8
9. Alving CR, Steck EA, Chapman WL, Jr., Waits VB, Hendricks LD, Swartz GM, Jr., et al. Therapy of leishmaniasis: superior efficacies of liposome-encapsulated drugs. Proc Natl Acad Sci USA. 1978; 75: 2959-63
10. Scherphof GL, Dijkstra J, Spanjer HH, Derksen JT, Roerdink FH. Uptake and intracellular processing of targeted and nontargeted liposomes by rat Kupffer cells in vivo and in vitro. Ann NY Acad Sci. 1985; 446: 368-84
11. Patel HM. Serum Opsonins and Liposomes-Their Interaction and Opsonophagocytosis. Crit Rev Ther Drug. 1992; 9: 39-90
12. Plotnick AN. Lipid-based formulations of amphotericin B. J Am Vet Med Assoc. 2000; 216: 838-41
13. Svenson S. Clinical translation of nanomedicines. Curr Opin Solid St M. 2012; 16: 287-94
14. Marrink SJ, Mark AE. The mechanism of vesicle fusion as revealed by molecular dynamics simulations. J Am Chem Soc. 2003; 125: 11144-5
15. Haluska CK, Riske KA, Marchi-Artzner V, Lehn JM, Lipowsky R, Dimova R. Time scales of membrane fusion revealed by direct imaging of vesicle fusion with high temporal resolution. Proc Natl Acad Sci USA. 2006; 103: 15841-6
16. Blume G, Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim Biophys Acta. 1993; 1146: 157-68
17. Senior J, Gregoriadis G. Is Half-Life of Circulating Liposomes Determined by Changes in Their Permeability. FEBS Lett. 1982; 145: 109-14
18. Gabizon A, Papahadjopoulos D. Liposome Formulations with Prolonged Circulation Time in Blood and Enhanced Uptake by Tumors. Proc Natl Acad Sci USA. 1988; 85: 6949-53
19. Woodle MC. Sterically Stabilized Liposome Therapeutics. Adv Drug Deliver Rev. 1995; 16: 249-65
20. Immordino ML, Dosio F, Cattel L. Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int J Nanomed. 2006; 1: 297-315
21. Allen TM, Hansen C, Martin F, Redemann C, Yauyoung A. Liposomes Containing Synthetic Lipid Derivatives of Poly(Ethylene Glycol) Show Prolonged Circulation Half-Lives In Vivo. Biochim Biophys Acta. 1991; 1066: 29-36
22. Drummond DC, Meyer O, Hong KL, Kirpotin DB, Papahadjopoulos D. Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol Rev. 1999; 51: 691-743
23. Maeda H, Sawa T, Konno T. Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J Control Release. 2001; 74: 47-61
24. Allen C, Dos Santos N, Gallagher R, Chiu GNC, Shu Y, Li WM, et al. Controlling the physical behavior and biological performance of liposome formulations through use of surface grafted poly(ethylene glycol). Bioscience Rep. 2002; 22: 225-50
25. Caliceti P, Veronese FM. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv Drug Deliver Rev. 2003; 55: 1261-77
26. Barenholz Y. Doxil(R)-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160: 117-34
27. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal Doxorubicin: review of animal and human studies. Clin Pharmacokinet. 2003; 42: 419-36
28. Gao WW, Hu CMJ, Fang RH, Zhang LF. Liposome-like nanostructures for drug delivery. J Mater Chem B. 2013; 1: 6569-85
29. Malam Y, Loizidou M, Seifalian AM. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer. Trends Pharmacol Sci. 2009; 30: 592-9
30. Lian T, Ho RJ. Trends and developments in liposome drug delivery systems. J Pharm Sci. 2001; 90: 667-80
31. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliver Rev. 2014; 66: 2-25
32. Strijkers GJ, Mulder WJM, van Heeswijk RB, Frederik PM, Bomans P, Magusin PCMM, et al. Relaxivity of liposomal paramagnetic MRI contrast agents. Magn Reson Mater Phy. 2005; 18: 186-92
33. Abra RM, Schreier H, Szoka FC. The Use of a New Radioactive-Iodine Labeled Lipid Marker to Follow Invivo Disposition of Liposomes-Comparison with an Encapsulated Aqueous Space Marker. Res Commun Chem Pathol Pharmacol. 1982; 37: 199-213
34. Phillips WT, Goins BA, Bao A. Radioactive liposomes. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009; 1: 69-83
35. Zhang LF, Granick S. How to stabilize phospholipid liposomes (using nanoparticles). Nano Lett. 2006; 6: 694-8
36. Michel R, Plostica T, Abezgauz L, Danino D, Gradzielski M. Control of the stability and structure of liposomes by means of nanoparticles. Soft Matter. 2013; 9: 4167-77
37. Liu JW, Jiang XM, Ashley C, Brinker CJ. Electrostatically Mediated Liposome Fusion and Lipid Exchange with a Nanoparticle-Supported Bilayer for Control of Surface Charge, Drug Containment, and Delivery. J Am Chem Soc. 2009; 131: 7567-9
38. Liu JW, Stace-Naughton A, Jiang XM, Brinker CJ. Porous Nanoparticle Supported Lipid Bilayers (Protocells) as Delivery Vehicles. J Am Chem Soc. 2009; 131: 1354-5
39. Weissleder R, Pittet MJ. Imaging in the era of molecular oncology. Nature. 2008; 452: 580-9
40. Al-Jamal WT, Al-Jamal KT, Bomans PH, Frederik PM, Kostarelos K. Functionalized-quantum-dot-liposome hybrids as multimodal nanoparticles for cancer. Small. 2008; 4: 1406-15
41. Min YZ, Li JM, Liu F, Padmanabhan P, Yeow EKL, Xing BG. Recent Advance of Biological Molecular Imaging Based on Lanthanide-Doped Upconversion-Luminescent Nanomaterials. Nanomaterials. 2014; 4: 129-54
42. Hilderbrand SA, Weissleder R. Near-infrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol. 2010; 14: 71-9
43. Eliseeva SV, Bunzli JCG. Lanthanide luminescence for functional materials and bio-sciences. Chem Soc Rev. 2010; 39: 189-227
44. Bunzli JCG. Lanthanide Luminescence for Biomedical Analyses and Imaging. Chem Rev. 2010; 110: 2729-55
45. Soga K, Tokuzen K, Tsuji K, Yamano T, Hyodo H, Kishimoto H. NIR Bioimaging: Development of Liposome-Encapsulated, Rare-Earth-Doped Y2O3 Nanoparticles as Fluorescent Probes. Eur J Inorg Chem. 2010: 2673-7
46. Sun C, Lee JSH, Zhang MQ. Magnetic nanoparticles in MR imaging and drug delivery. Adv Drug Deliver Rev. 2008; 60: 1252-65
47. Que EL, Domaille DW, Chang CJ. Metals in neurobiology: Probing their chemistry and biology with molecular imaging. Chem Rev. 2008; 108: 1517-49
48. Kamaly N, Kalber T, Thanou M, Bell JD, Miller AD. Folate Receptor Targeted Bimodal Liposomes for Tumor Magnetic Resonance Imaging. Bioconjugate Chem. 2009; 20: 648-55
49. Soenen SJ, Vande Velde G, Ketkar-Atre A, Himmelreich U, De Cuyper M. Magnetoliposomes as magnetic resonance imaging contrast agents. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2011; 3: 197-211
50. Tagami T, Foltz WD, Ernsting MJ, Lee CM, Tannock IF, May JP, et al. MRI monitoring of intratumoral drug delivery and prediction of the therapeutic effect with a multifunctional thermosensitive liposome. Biomaterials. 2011; 32: 6570-8
51. Mikhaylov G, Mikac U, Magaeva AA, Itin VI, Naiden EP, Psakhye I, et al. Ferri-liposomes as an MRI-visible drug-delivery system for targeting tumours and their microenvironment. Nat Nanotechnol. 2011; 6: 594-602
52. Cheng HD, Shan J, Ju W, Guo YH, Zhang L. Automated breast cancer detection and classification using ultrasound images: A survey. Pattern Recogn. 2010; 43: 299-317
53. Deckers R, Moonen CTW. Ultrasound triggered, image guided, local drug delivery. J Control Release. 2010; 148: 25-33
54. Ferrara KW, Borden MA, Zhang H. Lipid-Shelled Vehicles: Engineering for Ultrasound Molecular Imaging and Drug Delivery. Acc Chem Res. 2009; 42: 881-92
55. Kodama T, Tomita N, Yagishita Y, Horie S, Funamoto K, Hayase T, et al. h. Cancer Res. 2011; 71: 6957-64
56. Srivatsan A, Chen XY. Recent Advances in Nanoparticle-Based Nuclear Imaging of Cancers. Emerging Applications of Molecular Imaging to Oncology. 2014; 124: 83-129
57. Rahmim A, Zaidi H. PET versus SPECT: strengths, limitations and challenges. Nucl Med Commun. 2008; 29: 193-207
58. Seo JW, Zhang H, Kukis DL, Meares CF, Ferrara KW. A Novel Method to Label Preformed Liposomes with 64Cu for Positron Emission Tomography (PET) Imaging. Bioconjugate Chem. 2008; 19: 2577-84
59. Petersen AL, Binderup T, Rasmussen P, Henriksen JR, Elema DR, Kjaer A, et al. 64Cu loaded liposomes as positron emission tomography imaging agents. Biomaterials. 2011; 32: 2334-41
60. Henriksen JR, Petersen AL, Hansen AE, Frankaer CG, Harris P, Elema DR, et al. Remote Loading of 64Cu2+ into Liposomes without the Use of Ion Transport Enhancers. ACS Appl Mater Interfaces. 2015; 7: 22796-806
61. Ogawa M, Umeda IO, Kosugi M, Kawai A, Hamaya Y, Takashima M, et al. Development of In-111-Labeled Liposomes for Vulnerable Atherosclerotic Plaque Imaging. J Nucl Med. 2014; 55: 115-20
62. Paoli EE, Kruse DE, Seo JW, Zhang H, Kheirolomoom A, Watson KD, et al. An optical and microPET assessment of thermally-sensitive liposome biodistribution in the Met-1 tumor model: Importance of formulation. J Control Release. 2010; 143: 13-22
63. Chang YJ, Chang CH, Yu CY, Chang TJ, Chen LC, Chen MH, et al. Therapeutic efficacy and microSPECT/CT imaging of Re-188-DXR-liposome in a C26 murine colon carcinoma solid tumor model. Nucl Med Biol. 2010; 37: 95-104
64. Bally M, Bailey K, Sugihara K, Grieshaber D, Voros J, Stadler B. Liposome and Lipid Bilayer Arrays Towards Biosensing Applications. Small. 2010; 6: 2481-97
65. Bally M, Voros J. Nanoscale labels: nanoparticles and liposomes in the development of high-performance biosensors. Nanomedicine. 2009; 4: 447-67
66. Liu QT, Boyd BJ. Liposomes in biosensors. Analyst. 2013; 138: 391-409
67. Chen WY, Chen LY, Ou CM, Huang CC, Wei SC, Chang HT. Synthesis of Fluorescent Gold Nanodot-Liposome Hybrids for Detection of Phospholipase C and Its Inhibitor. Anal Chem. 2013; 85: 8834-40
68. Chaize B, Nguyen M, Ruysschaert T, le Berre V, Trevisiol E, Caminade AM, et al. Microstructured liposome array. Bioconjugate Chem. 2006; 17: 245-7
69. Fujii S, Matsuura T, Sunami T, Kazuta Y, Yomo T. In vitro evolution of alpha-hemolysin using a liposome display. Proc Natl Acad Sci USA. 2013; 110: 16796-801
70. Fujii S, Matsuura T, Sunami T, Nishikawa T, Kazuta Y, Yomo T. Liposome display for in vitro selection and evolution of membrane proteins. Nat Protoc. 2014; 9: 1578-91
71. Rodriguez-Pulido A, Kondrachuk AI, Prusty DK, Gao J, Loi MA, Herrmann A. Light-Triggered Sequence-Specific Cargo Release from DNA Block Copolymer-Lipid Vesicles. Angew Chem Int Ed. 2013; 52: 1008-12
72. Gunnarsson A, Sjovall P, Hook F. Liposome-Based Chemical Barcodes for Single Molecule DNA Detection Using Imaging Mass Spectrometry. Nano Lett. 2010; 10: 732-7
73. Zhou J, Wang QX, Zhang CY. Liposome-Quantum Dot Complexes Enable Multiplexed Detection of Attomolar DNAs without Target Amplification. J Am Chem Soc. 2013; 135: 2056-9
74. Yigit MV, Mishra A, Tong R, Cheng JJ, Wong GCL, Lu Y. Inorganic Mercury Detection and Controlled Release of Chelating Agents from Ion-Responsive Liposomes. Chem Biol. 2009; 16: 937-42
75. Chung MF, Chen KJ, Liang HF, Liao ZX, Chia WT, Xia YN, et al. A Liposomal System Capable of Generating CO2 Bubbles to Induce Transient Cavitation, Lysosomal Rupturing, and Cell Necrosis. Angew Chem Int Ed. 2012; 51: 10089-93
76. Dong RJ, Zhu BS, Zhou YF, Yan DY, Zhu XY. "Breathing" Vesicles with Jellyfish-like On-Off Switchable Fluorescence Behavior. Angew Chem Int Ed. 2012; 51: 11633-7
77. Xing H, Zhang CL, Ruan G, Zhang JJ, Hwang K, Lu Y. Multimodal Detection of a Small Molecule Target Using Stimuli-Responsive Liposome Triggered by Aptamer-Enzyme Conjugate. Anal Chem. 2016; 88: 1506-10
78. Kim KM, Oh DJ, Ahn KH. Zinc(II)-Dipicolylamine-Functionalized Polydiacetylene-Liposome Microarray: A Selective and Sensitive Sensing Platform for Pyrophosphate Ions. Chem Asian J. 2011; 6: 122-7
79. Lee J, Kim HJ, Kim J. Polydiacetylene liposome arrays for selective potassium detection. J Am Chem Soc. 2008; 130: 5010-1
80. Lee J, Jun H, Kim J. Polydiacetylene-Liposome Microarrays for Selective and Sensitive Mercury(II) Detection. Adv Mater. 2009; 21: 3674-7
81. Chang HI, Yeh MK. Clinical development of liposome-based drugs: formulation, characterization, and therapeutic efficacy. Int J Nanomed. 2012; 7: 49-60
82. Pattni BS, Chupin VV, Torchilin VP. New Developments in Liposomal Drug Delivery. Chem Rev. 2015; 115: 10938-66
83. Mamot C, Ritschard R, Wicki A, Stehle G, Dieterle T, Bubendorf L, et al. Tolerability, safety, pharmacokinetics, and efficacy of doxorubicin-loaded anti-EGFR immunoliposomes in advanced solid tumours: a phase 1 dose-escalation study. Lancet Oncol. 2012; 13: 1234-41
84. Wu YL, Park K, Soo RA, Sun Y, Tyroller K, Wages D, et al. INSPIRE: A phase III study of the BLP25 liposome vaccine (L-BLP25) in Asian patients with unresectable stage III non-small cell lung cancer. BMC Cancer. 2011; 11: 430
85. Ko AH, Tempero MA, Shan YS, Su WC, Lin YL, Dito E, et al. A multinational phase 2 study of nanoliposomal irinotecan sucrosofate (PEP02, MM-398) for patients with gemcitabine-refractory metastatic pancreatic cancer. Br J Cancer. 2013; 109: 920-5
86. Casagrande N, Celegato M, Borghese C, Mongiat M, Colombatti A, Aldinucci D. Preclinical activity of the liposomal cisplatin lipoplatin in ovarian cancer. Clin Cancer Res. 2014; 20: 5496-506
87. Gaillard PJ, Kerklaan BM, Aftimos P, Altintas S, Jager A, Gladdines W, et al. Phase I dose escalating study of 2B3-101, glutathione PEGylated liposomal doxorubicin, in patients with solid tumors and brain metastases or recurrent malignant glioma. Cancer Res. 2014; 74
88. Barenholz Y. Doxil (R)-The first FDA-approved nano-drug: Lessons learned. J Control Release. 2012; 160: 117-34
89. Woodle MC. Controlling liposome blood clearance by surface-grafted polymers. Adv Drug Deliver Rev. 1998; 32: 139-52
90. Eliaz RE, Szoka FC. Liposome-encapsulated doxorubicin targeted to CD44: A strategy to kill CD44-overexpressing tumor cells. Cancer Res. 2001; 61: 2592-601
91. Lee RJ, Low PS. Folate-Mediated Tumor-Cell Targeting of Liposome-Entrapped Doxorubicin in-Vitro. BBA Biomembranes. 1995; 1233: 134-44
92. Gabizon A, Shmeeda H, Horowitz AT, Zalipsky S. Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates. Adv Drug Deliver Rev. 2004; 56: 1177-92
93. Song SX, Liu D, Peng JL, Sun Y, Li ZH, Gu JR, et al. Peptide ligand-mediated liposome distribution and targeting to EGFR expressing tumor in vivo. Int J Pharm. 2008; 363: 155-61
94. Kang HZ, O'Donoghue MB, Liu HP, Tan WH. A liposome-based nanostructure for aptamer directed delivery. Chem Commun. 2010; 46: 249-51
95. Cao ZH, Tong R, Mishra A, Xu WC, Wong GCL, Cheng JJ, et al. Reversible Cell-Specific Drug Delivery with Aptamer-Functionalized Liposomes. Angew Chem Int Ed. 2009; 48: 6494-8
96. Xing H, Tang L, Yang XJ, Hwang K, Wang WD, Yin Q, et al. Selective delivery of an anticancer drug with aptamer-functionalized liposomes to breast cancer cells in vitro and in vivo. J Mater Chem B. 2013; 1: 5288-97
97. Xing H, Li J, Xu W, Hwang K, Wu P, Yin Q, et al. The Effects of Spacer Length and Composition on Aptamer-Mediated Cell-Specific Targeting with Nanoscale PEGylated Liposomal Doxorubicin. ChemBioChem. 2016: DOI: 10.1002/cbic.201600092
98. Zhu L, Kate P, Torchilin VP. Matrix Metalloprotease 2-Responsive Multifunctional Liposomal Nanocarrier for Enhanced Tumor Targeting. ACS Nano. 2012; 6: 3491-8
99. Peiris PM, Bauer L, Toy R, Tran E, Pansky J, Doolittle E, et al. Enhanced Delivery of Chemotherapy to Tumors Using a Multicomponent Nanochain with Radio-Frequency-Tunable Drug Release. ACS Nano. 2012; 6: 4157-68
100. Obonyo M, Zhang L, Thamphiwatana S, Pornpattananangkul D, Fu V, Zhang LF. Antibacterial Activities of Liposomal Linolenic Acids against Antibiotic-Resistant Helicobacter pylori. Mol Pharm. 2012; 9: 2677-85
101. Szebeni J, Bedocs P, Rozsnyay Z, Weiszhar Z, Urbanics R, Rosivall L, et al. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome. Nanomedicine. 2012; 8: 176-84
102. Forster V, Signorell RD, Roveri M, Leroux JC. Liposome-supported peritoneal dialysis for detoxification of drugs and endogenous metabolites. Sci Transl Med. 2014; 6
103. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA: Liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol. 1997; 15: 647-52
104. Gao X, Huang L. Cationic liposome-mediated gene transfer. Gene Ther. 1995; 2: 710-22
105. Templeton NS, Lasic DD. New directions in liposome gene delivery. Mol Biotechnol. 1999; 11: 175-80
106. Ewert KK, Zidovska A, Ahmad A, Bouxsein NF, Evans HM, McAllister CS, et al. Cationic Liposome-Nucleic Acid Complexes for Gene Delivery and Silencing: Pathways and Mechanisms for Plasmid DNA and siRNA. Nucleic Acid Transfection. 2010; 296: 191-226
107. Schafer J, Hobel S, Bakowsky U, Aigner A. Liposome-polyethylenimine complexes for enhanced DNA and siRNA delivery. Biomaterials. 2010; 31: 6892-900
108. Tagalakis AD, He L, Saraiva L, Gustafsson KT, Hart SL. Receptor-targeted liposome-peptide nanocomplexes for siRNA delivery. Biomaterials. 2011; 32: 6302-15
109. Wang HJ, Zhao PQ, Su WY, Wang S, Liao ZY, Niu RF, et al. PLGA/polymeric liposome for targeted drug and gene co-delivery. Biomaterials. 2010; 31: 8741-8
110. Sahay G, Querbes W, Alabi C, Eltoukhy A, Sarkar S, Zurenko C, et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat Biotechnol. 2013; 31: 653-U119
111. Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, et al. Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. Proc Natl Acad Sci USA. 1996; 93: 15388-93
112. Butts C, Murray N, Maksymiuk A, Goss G, Marshall E, Soulieres D, et al. Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol. 2005; 23: 6674-81
113. Chaplin DD. Overview of the immune response. J Allergy Clin Immun. 2010; 125: S3-S23
114. Parkin J, Cohen B. An overview of the immune system. Lancet. 2001; 357: 1777-89
115. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: Influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine. 2012; 30: 2256-72
116. Ma YF, Zhuang Y, Xie XF, Wang C, Wang F, Zhou DM, et al. The role of surface charge density in cationic liposome-promoted dendritic cell maturation and vaccine-induced immune responses. Nanoscale. 2011; 3: 2307-14
117. Miyabe H, Hyodo M, Nakamura T, Sato Y, Hayakawa Y, Harashima H. A new adjuvant delivery system 'cyclic di-GMP/YSK05 liposome' for cancer immunotherapy. J Control Release. 2014; 184: 20-7
118. Radovic-Moreno AF, Chernyak N, Mader CC, Nallagatla S, Kang RS, Hao LL, et al. Immunomodulatory spherical nucleic acids. Proc Natl Acad Sci USA. 2015; 112: 3892-7
119. Kelkar SS, Reineke TM. Theranostics: Combining Imaging and Therapy. Bioconjugate Chem. 2011; 22: 1879-903
120. Ostrowski AD, Lin BF, Tirrell MV, Ford PC. Liposome Encapsulation of a Photochemical NO Precursor for Controlled Nitric Oxide Release and Simultaneous Fluorescence Imaging. Mol Pharm. 2012; 9: 2950-5
121. Lozano N, Al-Ahmady ZS, Beziere NS, Ntziachristos V, Kostarelos K. Monoclonal antibody-targeted PEGylated liposome-ICG encapsulating doxorubicin as a potential theranostic agent. Int J Pharm. 2015; 482: 2-10
122. Li SH, Goins B, Zhang LJ, Bao AD. Novel Multifunctional Theranostic Liposome Drug Delivery System: Construction, Characterization, and Multimodality MR, Near-Infrared Fluorescent, and Nuclear Imaging. Bioconjugate Chem. 2012; 23: 1322-32
123. Ren LL, Chen SZ, Li HD, Zhang ZY, Ye CH, Liu ML, et al. MRI-visible liposome nanovehicles for potential tumor-targeted delivery of multimodal therapies. Nanoscale. 2015; 7: 12843-50
124. Wallner J, Lhota G, Jeschek D, Mader A, Vorauer-Uhl K. Application of Bio-Layer Interferometry for the analysis of protein/liposome interactions. J Pharmaceut Biomed. 2013; 72: 150-4
125. Saliba AE, Vonkova I, Ceschia S, Findlay GM, Maeda K, Tischer C, et al. A quantitative liposome microarray to systematically characterize protein-lipid interactions. Nat Methods. 2014; 11: 47-50
126. Marsden HR, Korobko AV, Zheng TT, Voskuhl J, Kros A. Controlled liposome fusion mediated by SNARE protein mimics. Biomater Sci. 2013; 1: 1046-54
127. Fang XH, Tan WH. Aptamers Generated from Cell-SELEX for Molecular Medicine: A Chemical Biology Approach. Acc Chem Res. 2010; 43: 48-57
128. Amenitsch H, Caracciolo G, Foglia P, Fuscoletti V, Giansanti P, Marianecci C, et al. Existence of hybrid structures in cationic liposome/DNA complexes revealed by their interaction with plasma proteins. Colloid Surface B. 2011; 82: 141-6
129. Duzgunes N, Nir S. Mechanisms and kinetics of liposome-cell interactions. Adv Drug Deliver Rev. 1999; 40: 3-18
130. Duzgunes N, Faneca H, de Lima MCP. Methods to Monitor Liposome Fusion, Permeability, and Interaction with Cells. Liposomes: Methods and Protocols, Vol 2. 2010; 606: 209-32
131. Almofti MR, Harashima H, Shinohara Y, Almofti A, Baba Y, Kiwada H. Cationic liposome-mediated gene delivery: Biophysical study and mechanism of internalization. Arch Biochem Biophys. 2003; 410: 246-53
132. Lynge ME, Ogaki R, Laursen AO, Lovmand J, Sutherland DS, Stadler B. Polydopamine/Liposome Coatings and Their Interaction with Myoblast Cells. ACS Appl Mater Interfaces. 2011; 3: 2142-7
133. Muppidi K, Wang J, Betageri G, Pumerantz AS. PEGylated Liposome Encapsulation Increases the Lung Tissue Concentration of Vancomycin. Antimicrob Agents Ch. 2011; 55: 4537-42
134. Shmeeda H, Amitay Y, Tzemach D, Gorin J, Gabizon A. Liposome encapsulation of zoledronic acid results in major changes in tissue distribution and increase in toxicity. J Control Release. 2013; 167: 265-75
135. Lozano N, Al-Jamal WT, Taruttis A, Beziere N, Burton NC, Van den Bossche J, et al. Liposome-Gold Nanorod Hybrids for High-Resolution Visualization Deep in Tissues. J Am Chem Soc. 2012; 134: 13256-8
136. Akinc A, Zumbuehl A, Goldberg M, Leshchiner ES, Busini V, Hossain N, et al. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics. Nat Biotechnol. 2008; 26: 561-9
137. Whitehead KA, Dorkin JR, Vegas AJ, Chang PH, Veiseh O, Matthews J, et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat Commun. 2014; 5
138. Chen DL, Love KT, Chen Y, Eltoukhy AA, Kastrup C, Sahay G, et al. Rapid Discovery of Potent siRNA-Containing Lipid Nanoparticles Enabled by Controlled Microfluidic Formulation. J Am Chem Soc. 2012; 134: 6948-51
139. Kauffman KJ, Dorkin JR, Yang JH, Heartlein MW, DeRosa F, Mir FF, et al. Optimization of Lipid Nanoparticle Formulations for mRNA Delivery in Vivo with Fractional Factorial and Definitive Screening Designs. Nano Lett. 2015; 15: 7300-6
140. Hu CMJ, Zhang L, Aryal S, Cheung C, Fang RH, Zhang LF. Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platform. Proc Natl Acad Sci USA. 2011; 108: 10980-5
141. Hu CMJ, Fang RH, Copp J, Luk BT, Zhang LF. A biomimetic nanosponge that absorbs pore-forming toxins. Nat Nanotechnol. 2013; 8: 336-40
142. Hu CMJ, Fang RH, Luk BT, Zhang LF. Nanoparticle-detained toxins for safe and effective vaccination. Nat Nanotechnol. 2013; 8: 933-8
143. Hu CMJ, Fang RH, Wang KC, Luk BT, Thamphiwatana S, Dehaini D, et al. Nanoparticle biointerfacing by platelet membrane cloaking. Nature. 2015; 526: 118-21
144. Shi JJ, Xiao ZY, Kamaly N, Farokhzad OC. Self-Assembled Targeted Nanoparticles: Evolution of Technologies and Bench to Bedside Translation. Acc Chem Res. 2011; 44: 1123-34
145. Chen ML. Lipid excipients and delivery systems for pharmaceutical development: A regulatory perspective. Adv Drug Deliver Rev. 2008; 60: 768-77